IL137848A0 - Indole-3-propionic acids, salts and esters thereof used as medicaments - Google Patents
Indole-3-propionic acids, salts and esters thereof used as medicamentsInfo
- Publication number
- IL137848A0 IL137848A0 IL13784899A IL13784899A IL137848A0 IL 137848 A0 IL137848 A0 IL 137848A0 IL 13784899 A IL13784899 A IL 13784899A IL 13784899 A IL13784899 A IL 13784899A IL 137848 A0 IL137848 A0 IL 137848A0
- Authority
- IL
- Israel
- Prior art keywords
- indole
- ester
- salt
- propionic acid
- effective amount
- Prior art date
Links
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical class C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 title abstract 9
- 150000002148 esters Chemical class 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title 1
- 239000003290 indole 3-propionic acid Substances 0.000 abstract 4
- 239000012472 biological sample Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000035557 fibrillogenesis Effects 0.000 abstract 1
- 230000002600 fibrillogenic effect Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7555598P | 1998-02-23 | 1998-02-23 | |
| US11256598P | 1998-12-16 | 1998-12-16 | |
| PCT/US1999/003906 WO1999042102A1 (en) | 1998-02-23 | 1999-02-23 | Indole-3-propionic acids, salts and esters thereof used as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL137848A0 true IL137848A0 (en) | 2001-10-31 |
Family
ID=26757006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13784899A IL137848A0 (en) | 1998-02-23 | 1999-02-23 | Indole-3-propionic acids, salts and esters thereof used as medicaments |
| IL137848A IL137848A (en) | 1998-02-23 | 2000-08-14 | Indole-3-propionic acids and salts and esters thereof for use as medicaments |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL137848A IL137848A (en) | 1998-02-23 | 2000-08-14 | Indole-3-propionic acids and salts and esters thereof for use as medicaments |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6395768B1 (da) |
| EP (1) | EP1056452B1 (da) |
| JP (2) | JP5627160B2 (da) |
| CN (1) | CN1147299C (da) |
| AT (1) | ATE333275T1 (da) |
| AU (1) | AU757925B2 (da) |
| BR (1) | BR9908165A (da) |
| CA (1) | CA2321455C (da) |
| DE (1) | DE69932414T2 (da) |
| DK (1) | DK1056452T3 (da) |
| EA (1) | EA005244B1 (da) |
| ES (1) | ES2270585T3 (da) |
| IL (2) | IL137848A0 (da) |
| MX (1) | MXPA00008216A (da) |
| NZ (1) | NZ506260A (da) |
| PT (1) | PT1056452E (da) |
| WO (1) | WO1999042102A1 (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419916B1 (en) | 1999-06-01 | 2002-07-16 | The Regents Of The University Of California | Assay for compounds which affect conformationally altered proteins |
| US6719988B2 (en) | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Antiseptic compositions for inactivating prions |
| US6322802B1 (en) | 1999-06-01 | 2001-11-27 | The Regents Of The University Of California | Method of sterilizing |
| US6720355B2 (en) | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Sodium dodecyl sulfate compositions for inactivating prions |
| DE10006139A1 (de) * | 2000-02-11 | 2001-08-16 | Merck Patent Gmbh | Indol-3-yl-Derivate |
| US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| EP1583713B1 (en) | 2003-01-07 | 2009-03-25 | Ramot at Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| KR101415503B1 (ko) * | 2003-07-17 | 2014-07-04 | 플렉시콘, 인코퍼레이티드 | Ppar 활성 화합물 |
| US7125861B2 (en) * | 2003-07-31 | 2006-10-24 | Rolland F Hebert | Water-soluble chitosan-indole-3-propionic acid conjugates |
| WO2005027901A1 (en) | 2003-09-25 | 2005-03-31 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
| WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| US20070105937A1 (en) * | 2003-12-22 | 2007-05-10 | Miguel Pappolla | Indole-3-propionamide and derivatives thereof |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| US7732479B2 (en) | 2004-08-19 | 2010-06-08 | Tel Aviv University Future Technology Development L.P. | Compositions for treating amyloid associated diseases |
| JP2008521831A (ja) * | 2004-11-30 | 2008-06-26 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
| US7531568B2 (en) * | 2004-11-30 | 2009-05-12 | Plexxikon, Inc. | PPAR active compounds |
| EP1893576A4 (en) * | 2005-05-27 | 2010-03-17 | Univ Kingston | TREATMENT OF PROTEIN DISORDERING |
| EP1940767A2 (en) * | 2005-09-07 | 2008-07-09 | Plexxikon, Inc. | Pparactive compounds |
| AU2006287528A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as PPAR active compounds |
| EP1973928A2 (en) | 2005-10-11 | 2008-10-01 | Ramot at Tel-Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
| AU2007286651A1 (en) * | 2006-08-23 | 2008-02-28 | Intellect Neurosciences Inc. | 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom |
| PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| US9744155B2 (en) * | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| WO2015116988A2 (en) * | 2014-01-31 | 2015-08-06 | Counterpoint Health Solutions, Inc. | Covalently bound metabolites as biomarkers |
| CN108125950B (zh) * | 2017-12-28 | 2020-09-25 | 崔明 | 吲哚丙酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途 |
| JP2020083827A (ja) * | 2018-11-27 | 2020-06-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | ケミカルシャペロンまたは神経細胞死の抑制剤 |
| US11041847B1 (en) | 2019-01-25 | 2021-06-22 | Ixcela, Inc. | Detection and modification of gut microbial population |
| CN109674787A (zh) * | 2019-02-01 | 2019-04-26 | 百迈康生物医药科技(广州)有限公司 | 一种防治缺血性心脏病的药物及其应用 |
| CN109730993A (zh) * | 2019-02-28 | 2019-05-10 | 北京大学人民医院(北京大学第二临床医学院) | 吲哚丙酸在制备防治类风湿关节炎药物中的应用 |
| WO2020185913A1 (en) * | 2019-03-12 | 2020-09-17 | Intellect Neurosciences, Inc. | Indole-3-propionic acids and salts and esters thereof for treating skin disorders |
| US20230038360A1 (en) * | 2019-12-20 | 2023-02-09 | Basf Se | Composition for the treatment of amyloid-beta associated diseases |
| CN118141804A (zh) * | 2024-03-06 | 2024-06-07 | 浙江大学 | 吲哚-3-丙酸在制备用于增敏肿瘤免疫治疗的药物中的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536505A (en) * | 1983-05-17 | 1985-08-20 | Ciba-Geigy Corporation | Certain N-(pyridyl) indoles |
| JP2602735B2 (ja) * | 1989-09-27 | 1997-04-23 | 株式会社大塚製薬工場 | 抗活性酸素剤 |
| JPH0578248A (ja) * | 1991-03-04 | 1993-03-30 | Mitsubishi Gas Chem Co Inc | 活性酸素消去剤 |
| JPH0578247A (ja) * | 1991-03-04 | 1993-03-30 | Mitsubishi Gas Chem Co Inc | 活性酸素消去剤 |
| WO1993010087A1 (en) * | 1991-11-18 | 1993-05-27 | G.D. Searle & Co. | Derivatives of cyclic phenolic thioethers as inhibitors or stimulators of superoxide generation |
| CA2140440A1 (en) * | 1992-08-06 | 1994-02-17 | Ellen M. Dobrusin | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| IT1265101B1 (it) * | 1993-07-23 | 1996-10-30 | Erba Carlo Spa | Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico |
| JPH0881442A (ja) * | 1994-07-14 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 環状アミド誘導体 |
| RU2152385C1 (ru) * | 1994-07-27 | 2000-07-10 | Санкио Компани Лимитед | Гетероциклические соединения, применимые в качестве аллостерических эффекторов при мускариновых рецепторах |
| JPH08175993A (ja) * | 1994-12-21 | 1996-07-09 | Green Cross Corp:The | 抗酸化剤 |
| JPH09249567A (ja) * | 1996-01-12 | 1997-09-22 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| TW430660B (en) * | 1996-05-30 | 2001-04-21 | Mochida Pharm Co Ltd | Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them |
-
1999
- 1999-02-23 JP JP2000532118A patent/JP5627160B2/ja not_active Expired - Fee Related
- 1999-02-23 AT AT99908381T patent/ATE333275T1/de active
- 1999-02-23 CA CA2321455A patent/CA2321455C/en not_active Expired - Lifetime
- 1999-02-23 BR BR9908165-2A patent/BR9908165A/pt not_active Application Discontinuation
- 1999-02-23 CN CNB998032441A patent/CN1147299C/zh not_active Expired - Fee Related
- 1999-02-23 ES ES99908381T patent/ES2270585T3/es not_active Expired - Lifetime
- 1999-02-23 PT PT99908381T patent/PT1056452E/pt unknown
- 1999-02-23 EA EA200000874A patent/EA005244B1/ru not_active IP Right Cessation
- 1999-02-23 WO PCT/US1999/003906 patent/WO1999042102A1/en not_active Ceased
- 1999-02-23 IL IL13784899A patent/IL137848A0/xx unknown
- 1999-02-23 AU AU27828/99A patent/AU757925B2/en not_active Ceased
- 1999-02-23 MX MXPA00008216A patent/MXPA00008216A/es active IP Right Grant
- 1999-02-23 DE DE69932414T patent/DE69932414T2/de not_active Expired - Lifetime
- 1999-02-23 NZ NZ506260A patent/NZ506260A/en not_active IP Right Cessation
- 1999-02-23 EP EP99908381A patent/EP1056452B1/en not_active Expired - Lifetime
- 1999-02-23 DK DK99908381T patent/DK1056452T3/da active
-
2000
- 2000-05-30 US US09/580,437 patent/US6395768B1/en not_active Expired - Lifetime
- 2000-08-14 IL IL137848A patent/IL137848A/en not_active IP Right Cessation
-
2011
- 2011-10-20 JP JP2011230632A patent/JP2012017343A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1056452B1 (en) | 2006-07-19 |
| DK1056452T3 (da) | 2006-11-20 |
| PT1056452E (pt) | 2006-12-29 |
| CN1292693A (zh) | 2001-04-25 |
| BR9908165A (pt) | 2000-10-31 |
| AU2782899A (en) | 1999-09-06 |
| JP5627160B2 (ja) | 2014-11-19 |
| JP2002503691A (ja) | 2002-02-05 |
| DE69932414T2 (de) | 2007-02-22 |
| CA2321455C (en) | 2010-10-19 |
| WO1999042102A8 (en) | 2001-02-15 |
| EP1056452A1 (en) | 2000-12-06 |
| AU757925B2 (en) | 2003-03-13 |
| WO1999042102A1 (en) | 1999-08-26 |
| DE69932414D1 (de) | 2006-08-31 |
| CN1147299C (zh) | 2004-04-28 |
| EA005244B1 (ru) | 2004-12-30 |
| JP2012017343A (ja) | 2012-01-26 |
| US6395768B1 (en) | 2002-05-28 |
| MXPA00008216A (es) | 2004-11-22 |
| ATE333275T1 (de) | 2006-08-15 |
| CA2321455A1 (en) | 1999-08-26 |
| HK1036588A1 (en) | 2002-01-11 |
| ES2270585T3 (es) | 2007-04-01 |
| NZ506260A (en) | 2003-05-30 |
| IL137848A (en) | 2010-11-30 |
| EA200000874A1 (ru) | 2001-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL137848A (en) | Indole-3-propionic acids and salts and esters thereof for use as medicaments | |
| IT1176916B (it) | Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica | |
| DE69822832D1 (de) | Therapeutische und lebensmittel-zusammensetzungen, welche essentielle fettsäuren und bioaktive disulfide enthalten | |
| DE3778699D1 (de) | Verwendung von vitamin e zur herstellung von arzneimitteln zur normalisierung der blutgerinnung bei therapie mit hochungesaettigten fettsaeuren vom omega-3-typ. | |
| NO904378D0 (no) | Fremgangsmaate for fremstilling av et modifisert protein for terapeutisk anvendelse. | |
| EP0671162A3 (en) | Amphoteric compositions and polymer forms of alpha-hydroxy acids, and their therapeutic use. | |
| DE69031033D1 (de) | Verwendung von eicosapentaensäure zur behandlung der kachexie | |
| EP0733360A3 (en) | Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids | |
| ATE135208T1 (de) | Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen | |
| DE69636514D1 (de) | Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen | |
| EP0839529A3 (en) | Compositions containing aliphatic monocarboxylic acid esters or amides for the treatment of skin diseases | |
| ATE145554T1 (de) | Verwendung von kurzkettige fettsäuren enthaltenden lipiden zur aufrechterhaltung der integrität und der funktion des magen-darm-kanals | |
| EP0738146A1 (en) | Method of treating disorders of the animal or human body by administering amino acids | |
| CA2361070A1 (en) | Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid | |
| ITRM930365A0 (it) | Uso di esteri sull'ossidrile della l-carnitina con acidi aromatici perprodurre composizioni farmaceutiche per il trattamento di affezioni cutanee. | |
| SE8801710L (sv) | New ophtalmological composition of matter | |
| ATE86108T1 (de) | Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen. | |
| ES2044170T3 (es) | Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen. | |
| EP0396081A3 (en) | The use of phosphatidyl-carnitine for the preparation of pharmaceutical compositions having an activity in the therapy of human pathologies associated with neuronal damage | |
| FI891210A7 (fi) | Tiosulfiinihappojohdannaiset, niiden käyttö tulehdussairauksien käsitt elyyn sekä näitä aineita sisältävät lääkeaineet | |
| JPS56110679A (en) | 55aminootetrazole derivative of retinoic acid* its manufacture and medicine containing it | |
| ATE2746T1 (de) | Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen. | |
| ES2191825T3 (es) | Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia. | |
| IT1158029B (it) | Preparato per ridurre traumi dei tessuti in esseri umani o animali e procedeminto per la sua produzione | |
| JPS5695187A (en) | Piperidine derivative of 33hydroxyythiophenee 22carboxylic acid ester* its manufacture and medicine containing it |